SECsense Logo

Vanda Pharmaceuticals Inc. 8-K Filing: Stock Structure Insights and Compliance Report

$VNDA
Form 8-K
Filed on: 2025-02-20
Source
Vanda Pharmaceuticals Inc. 8-K Filing: Stock Structure Insights and Compliance Report

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Company Overview:
  • Name: Vanda Pharmaceuticals Inc.
  • Location: 2200 Pennsylvania Avenue NW Suite 300E, Washington, DC 20037.
  • Contact: (202) 734-3400.
  • SEC Identifier: CIK 0001347178.
  • Reporting Type: 8-K filing.
  • Ticker Symbol: VNDA (listed on NASDAQ).
  1. Stock Information:
  • The company has issued Common Stock with a par value of $0.001 per share.
  • Additionally, there is Series A Junior Preferred Stock Purchase Right also with a par value of $0.001 per share.
  1. Filing Details:
  • Filing Date: February 18, 2025.
  • The report is structured as per the US GAAP standards, indicating compliance with relevant accounting regulations.
  1. Context and Segmentation:
  • The report includes specific contexts for different classes of stock, including:
    • Common Stock.
    • Series A Junior Participating Preferred Stock Purchase Rights.
  • This indicates that the company has multiple classes of securities which could have different rights and privileges.
  1. XML and XBRL Structure:
  • The report utilizes XBRL (eXtensible Business Reporting Language) for structured financial reporting, which enhances data analysis and accessibility for investors.

This section of the report primarily focuses on the company’s stock structure and compliance with SEC reporting requirements, providing investors with essential information regarding its equity instruments.